159 related articles for article (PubMed ID: 37100777)
41. Six CT83-related Genes-based Prognostic Signature for Lung Adenocarcinoma.
Wang Y; Zhang G; Wang R
Comb Chem High Throughput Screen; 2022; 25(9):1565-1575. PubMed ID: 34259140
[TBL] [Abstract][Full Text] [Related]
42. Identification of a Seven-lncRNA Immune Risk Signature and Construction of a Predictive Nomogram for Lung Adenocarcinoma.
Jin D; Song Y; Chen Y; Zhang P
Biomed Res Int; 2020; 2020():7929132. PubMed ID: 32596372
[TBL] [Abstract][Full Text] [Related]
43. A novel seven-long non-coding RNA signature predicts survival in early stage lung adenocarcinoma.
Chen M; Liu B; Xiao J; Yang Y; Zhang Y
Oncotarget; 2017 Feb; 8(9):14876-14886. PubMed ID: 28122330
[TBL] [Abstract][Full Text] [Related]
44. DNA methylation profiling to predict recurrence risk in stage Ι lung adenocarcinoma: Development and validation of a nomogram to clinical management.
Ma X; Cheng J; Zhao P; Li L; Tao K; Chen H
J Cell Mol Med; 2020 Jul; 24(13):7576-7589. PubMed ID: 32530136
[TBL] [Abstract][Full Text] [Related]
45. The Comprehensive Analysis Identified an Autophagy Signature for the Prognosis and the Immunotherapy Efficiency Prediction in Lung Adenocarcinoma.
Li X; Dai Z; Wu X; Zhang N; Zhang H; Wang Z; Zhang X; Liang X; Luo P; Zhang J; Liu Z; Zhou Y; Cheng Q; Chang R
Front Immunol; 2022; 13():749241. PubMed ID: 35529878
[TBL] [Abstract][Full Text] [Related]
46. A Cell Differentiation Trajectory-Related Signature for Predicting the Prognosis of Lung Adenocarcinoma.
Yang F; Zhao Y; Huang X; Zhang J; Zhang T
Genet Res (Camb); 2022; 2022():3483498. PubMed ID: 36072012
[TBL] [Abstract][Full Text] [Related]
47. Abnormal Expression and Prognostic Significance of Bone Morphogenetic Proteins and Their Receptors in Lung Adenocarcinoma.
Xu Z; Chen C
Biomed Res Int; 2021; 2021():6663990. PubMed ID: 34036102
[TBL] [Abstract][Full Text] [Related]
48. A Machine-Learning Approach to Developing a Predictive Signature Based on Transcriptome Profiling of Ground-Glass Opacities for Accurate Classification and Exploring the Immune Microenvironment of Early-Stage LUAD.
Zhao Z; Yin W; Peng X; Cai Q; He B; Shi S; Peng W; Tu G; Li Y; Li D; Tao Y; Peng M; Wang X; Yu F
Front Immunol; 2022; 13():872387. PubMed ID: 35693786
[TBL] [Abstract][Full Text] [Related]
49. Screening of Methylation Gene Sites as Prognostic Signature in Lung Adenocarcinoma.
Dong M; Yang Z; Li X; Zhang Z; Yin A
Yonsei Med J; 2020 Dec; 61(12):1013-1023. PubMed ID: 33251775
[TBL] [Abstract][Full Text] [Related]
50. Single-cell sequencing analysis and transcriptome analysis constructed the macrophage related gene-related signature in lung adenocarcinoma and verified by an independent cohort.
Li R; Tong R; Zhang Z; Deng M; Wang T; Hou G
Genomics; 2022 Nov; 114(6):110520. PubMed ID: 36372305
[TBL] [Abstract][Full Text] [Related]
51. Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
Li N; Wang J; Zhan X
Front Immunol; 2021; 12():752643. PubMed ID: 34887858
[TBL] [Abstract][Full Text] [Related]
52. A novel 14-gene signature for overall survival in lung adenocarcinoma based on the Bayesian hierarchical Cox proportional hazards model.
Sun N; Chu J; Hu W; Chen X; Yi N; Shen Y
Sci Rep; 2022 Jan; 12(1):27. PubMed ID: 34996932
[TBL] [Abstract][Full Text] [Related]
53. Characteristics of Fatty Acid Metabolism in Lung Adenocarcinoma to Guide Clinical Treatment.
Huang D; Tang E; Zhang T; Xu G
Front Immunol; 2022; 13():916284. PubMed ID: 35860256
[TBL] [Abstract][Full Text] [Related]
54. Exploration of predictive and prognostic alternative splicing signatures in lung adenocarcinoma using machine learning methods.
Cai Q; He B; Zhang P; Zhao Z; Peng X; Zhang Y; Xie H; Wang X
J Transl Med; 2020 Dec; 18(1):463. PubMed ID: 33287830
[TBL] [Abstract][Full Text] [Related]
55. Construction of a Redox-Related Prognostic Model with Predictive Value in Survival and Therapeutic Response for Patients with Lung Adenocarcinoma.
Xiao L; Li Q; Huang Y; Fan Z; Ma L; Liu B; Yuan X
J Healthc Eng; 2022; 2022():7651758. PubMed ID: 35251577
[TBL] [Abstract][Full Text] [Related]
56. Hypoxia-related gene signature for predicting LUAD patients' prognosis and immune microenvironment.
Chen J; Fu Y; Hu J; He J
Cytokine; 2022 Apr; 152():155820. PubMed ID: 35176657
[TBL] [Abstract][Full Text] [Related]
57. A Prognostic 14-Gene Expression Signature for Lung Adenocarcinoma: A Study Based on TCGA Data Mining.
Liu J; Hou S; Wang J; Chai Z; Hong X; Zhao T; Sun Z; Bai L; Gao H; Gao J; Chen G
Oxid Med Cell Longev; 2020; 2020():8847226. PubMed ID: 33414898
[TBL] [Abstract][Full Text] [Related]
58. Vesicle-mediated transport-related genes are prognostic predictors and are associated with tumor immunity in lung adenocarcinoma.
Qian C; Jiang Z; Zhou T; Wu T; Zhang Y; Huang J; Ouyang J; Dong Z; Wu G; Cao J
Front Immunol; 2022; 13():1034992. PubMed ID: 36524130
[TBL] [Abstract][Full Text] [Related]
59. Prognostic model of lung adenocarcinoma constructed by the CENPA complex genes is closely related to immune infiltration.
Zhou H; Bian T; Qian L; Zhao C; Zhang W; Zheng M; Zhou H; Liu L; Sun H; Li X; Zhang J; Liu Y
Pathol Res Pract; 2021 Dec; 228():153680. PubMed ID: 34798483
[TBL] [Abstract][Full Text] [Related]
60. A seven-gene prognostic model related to immune checkpoint PD-1 revealing overall survival in patients with lung adenocarcinoma.
Niu W; Jiang L
Math Biosci Eng; 2021 Jul; 18(5):6136-6154. PubMed ID: 34517527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
